glp-1 ibd GLPs as novel therapeutic options in IBD-potential mechanisms of action GLP-1 IBD obesity "inflammatory bowel

10.1111/anae.16454 [DOI] [PubMed] [Google Scholar] 37.Sen S, Potnuru PP, Hernandez N, Goehl C, Praestholm C, Sridhar S et al (2024) Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia

Nonlinear pharmacokinetic properties of mildronate capsules: a randomized, open-label, single- and multiple-dose study in healthy volunteers

Primary critical endpoint analysis The primary endpoint, mean venous umbilical cord blood erythrocyte GSH concentrations, was analyzed both in the FAS and PP populations using the nonparametric Kruskal-Wallis Test, without stratification for IPTB severity grade due to the small sample size

[DOI] [PubMed] [Google Scholar] 293.Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK

C.UzunosmanogluE.KocabeyogluS.KarakayaJ.IrkecM

References: Wilding JPH, Batterham RL, Davies M, et al